An upgraded version of carbapenem inactivation method to detect Bacteroides fragilis carbapenemase.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 12 07 2022
revised: 19 10 2022
accepted: 04 11 2022
pubmed: 28 11 2022
medline: 25 1 2023
entrez: 27 11 2022
Statut: ppublish

Résumé

An increase of carbapenemase-producing Bacteroides fragilis infections is observed. To detect such a resistance in B. fragilis, several tests exist that are expensive or show poor sensitivity and specificity. Therefore, we upgraded the Anaerobic Carbapenem Inactivation Method (Ana-CIM) to easily screen for carbapenemase-producing B. fragilis. The presence of carbapenemase cfiA gene was identified in 50 B. fragilis isolates by PCR. We modified the Ana-CIM by (1) increasing the bacterial inoculum, and (2) measuring the differences in diameter between the negative control and the testing disc. We correctly classified the cfiA-negative and positive isolates and could define a cut-off of positivity at 2 mm. Our modified Ana-CIM allowed to correctly discriminate the 31 cfiA-positive with meropenem MICs ranging from 1 to > 32 µg/mL. We anticipate that our modified Ana-CIM could be used in most clinical laboratories to easily screen for carbapenemase-producing B. fragilis, even at low levels.

Identifiants

pubmed: 36436310
pii: S0732-8893(22)00221-8
doi: 10.1016/j.diagmicrobio.2022.115857
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
carbapenemase EC 3.5.2.6
Carbapenems 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115857

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Nathan Nicolau-Guillaumet (N)

Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Laboratoire de bactériologie-Virologie-Hygiène hospitalière-Parasitologie-Mycologie, Reims, France.

Anaëlle Muggeo (A)

Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Laboratoire de bactériologie-Virologie-Hygiène hospitalière-Parasitologie-Mycologie, Reims, France.

Sophie Moussalih (S)

Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Reims, France.

Christophe de Champs (C)

Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Laboratoire de bactériologie-Virologie-Hygiène hospitalière-Parasitologie-Mycologie, Reims, France.

Alain Lozniewski (A)

Université de Lorraine, SIMPA, Stress Immunity Pathogens unit, Nancy, France; CHRU-Nancy, Service de Microbiologie, Nancy, France.

Corentine Alauzet (C)

Université de Lorraine, SIMPA, Stress Immunity Pathogens unit, Nancy, France; CHRU-Nancy, Service de Microbiologie, Nancy, France.

Thomas Guillard (T)

Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, Laboratoire de bactériologie-Virologie-Hygiène hospitalière-Parasitologie-Mycologie, Reims, France. Electronic address: tguillard@chu-reims.fr.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH